.
MergerLinks Header Logo

Announced

Completed

Curaleaf completed the acquisition of a 55% stake in Four 20 Pharma.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For55%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

medical cannabis

Private

Germany

Cross Border

Majority

Medical Supplies

Acquisition

Friendly

Single Bidder

Completed

cannabis retailer

Synopsis

Edit

Curaleaf, a provider of consumer products in cannabis, completed the acquisition of a 55% stake in Four 20 Pharma, a fully EU-GMP & GDP licensed German producer and distributor of medical cannabis. Financial terms were not disclosed. "Four 20 Pharma is a leading German distributor with a branded product that consumers love. They've captured significant market share in Germany by sourcing product from top EU-GMP certified suppliers around the world and building strong connections with German medical consumers by providing the highest quality flower in a namesake branded offering. As such, Four 20 Pharma is uniquely positioned to capitalize on Germany's conversion from a medical to an adult use market and we're thrilled to be partnering with their talented management team," Miles Worne, Curaleaf President.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US